Related Articles
Generic drug: tenapanor
Brand name: Ibsrela
What is Ibsrela (tenapanor), and how does it work?
Ibsrela (tenapanor) is a prescription medicine used in adults to treat:
- Irritable bowel syndrome with constipation (IBS-C). It is not known if Ibsrela is safe and effective in children less than 18 years of age.
What are the side effects of Ibsrela?
WARNING
RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
- Ibsrela is contraindicated in patients less than 6 years of age; in
nonclinical studies in young juvenile rats administration of tenapanor
caused deaths presumed to be due to dehydration. - Avoid use of Ibsrela in patients 6 years to less than 12 years of age.
- The safety and effectiveness of Ibsrela have not been established in
patients less than 18 years of age.
Ibsrela can cause serious side effects, including:
- Diarrhea is the most common serious side effect of Ibsrela, and it can sometimes be severe. Stop taking
Ibsrela and call your doctor if you develop severe diarrhea.
The other most common side effects of Ibsrela include:
- swelling, or a feeling of fullness or pressure in your abdomen (distension).
- gas (flatulence).
- dizziness.
These are not all the possible side effects of Ibsrela. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch.
What is the dosage for Ibsrela?
The recommended dosage of Ibsrela in adults is 50 mg orally twice daily.
- Take Ibsrela immediately prior to breakfast or the first meal of the day and immediately
prior to dinner. - If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not
take 2 doses at the same time.
What drugs interact with Ibsrela?
No information provided
Is Ibsrela safe to use while pregnant or breastfeeding?
- Tenapanor is minimally absorbed systemically, with plasma concentrations below the limit of quantification (less than 0.5 ng/mL) following oral administration. Therefore, maternal use is not expected to result in fetal exposure to the drug.
- The available data on Ibsrela exposure from a small number of pregnant women have not identified any drug associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes.
- There are no data available on the presence of tenapanor in either human or animal milk, its effects on milk production or its effects on the breastfed infant.
- The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for
Ibsrela and any potential adverse effects on the breastfed infant from
Ibsrela or from the underlying maternal condition.